GREENSBORO, N.C., & SAN CARLOS, Calif.--(EON: Enhanced Online News)--Solstas Lab Partners®, one of the nation's fastest-growing full-service laboratories, and Natera, a leading innovator in reproductive and prenatal genetic testing, today announced a distribution agreement that will make Natera’s non-invasive prenatal screening test, Panorama™, available to Solstas’ clients nationwide. Panorama was launched earlier this year for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turner syndrome). In August 2013 detection of triploidy was added.
“We have seen growing interest in non-invasive prenatal testing in recent months and are excited to partner with Natera to offer Panorama to our physicians and patients”
“We have seen growing interest in non-invasive prenatal testing in recent months and are excited to partner with Natera to offer Panorama to our physicians and patients,” said Joy Wilson, Solstas Patient Wellness Program Director. “We believe that non-invasive prenatal testing will continue to expand and we value the accuracy and breadth that Panorama offers to expecting parents.”
Added Matthew Rabinowitz, Ph.D., chief executive officer of Natera, “Solstas is a respected full-service laboratory and we are proud to have them as a partner as we expand distribution of Panorama. Clinical trials have demonstrated that our technology allows for unparalleled sensitivity and specificity in the detection of more chromosomal abnormalities than other tests on the market, and we look forward to expanding Panorama’s use with additional applications.”
Panorama uses a simple blood draw from the mother, examines cell-free DNA found in maternal blood originating from both mother and fetus, and can be performed within the first trimester of pregnancy, as early as nine weeks, without any risk to the fetus. Panorama’s technology analyzes, in a single reaction, 19,500 single nucleotide polymorphisms (SNPs), which are the most informative portions of an individual’s DNA. It utilizes the NATUS [Next-generation Aneuploidy Testing Using SNPs] algorithm, an advanced version of Natera’s proprietary informatics.
Across multiple clinical trials, Panorama has been validated globally for trisomy 21, trisomy 18, trisomy 13 and monosomy X with a sensitivity of greater than 99% for trisomy 21, trisomy 18 and trisomy 13, 92% for monosomy X, and a less than 0.1% false positive rate for all syndromes tested. Panorama’s clinical validation data was presented at the annual Society of Maternal Fetal Medicine Meeting on Feb. 15, 2013. The most recent independently led, blinded study was published in May 2013 in Prenatal Diagnosis from author Professor Nicolaides and The Fetal Medicine Foundation. Panorama is currently being evaluated in several other clinical trials for the detection of other genetic disorders, including XXY, XYY, and XXX.
Natera is a genetic testing company that has developed a proprietary bioinformatics-based technology (NATUS) to deliver accurate and comprehensive high-throughput testing for reproductive indications from tiny quantities of DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening tests to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit www.natera.com.
About Solstas Lab Partners
Solstas Lab Partners is one of the 10 largest full-service laboratories in the U.S., serving the Mid-Atlantic and Southern regions, as well as the District of Columbia. Solstas supports the unique needs of clients and their patients with a full range of clinical, anatomic pathology and esoteric testing services, as well as comprehensive Patient Wellness Programs. Our mission is to provide an exceptional laboratory experience for our clients and their patients. For more information, please contact Solstas at 1-888-664-7601 or visit www.solstas.com.